About Pasithea
Pasithea is a company based in Miami Beach (United States) founded in 2020 by Lawrence Steinman. It operates as a HealthTech. Pasithea has raised $1.46 million across 3 funding rounds. The company has 4 employees. Pasithea has completed 2 acquisitions, including Allomek Therapeutics and Alpha-5 Integrin. Pasithea offers products and services including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy. Pasithea operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Miami Beach, United States
- Employees 4
- Founders Lawrence Steinman
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pasithea.com
- Social LinkedIn X Facebook Instagram
- Legal Name Pasithea Therapeutics Corp.
- Net Profit-$20.43 M (USD)-46.91as on Dec 31, 2025
- EBITDA-$16.03 M (USD)-17.87as on Dec 31, 2025
- Total Equity Funding$1.46M (USD)
in 3 rounds
- Latest Funding Round$30.4M (USD), Post-IPO
Nov 2021
- Employee Count4
- Investments & AcquisitionsAllomek Therapeutics
& 1 more
Products & Services of Pasithea
Pasithea offers a comprehensive portfolio of products and services, including Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy.
Therapy for Neurofibromatosis Type 1 is being developed.
Therapy for ALS is researched for muscle control loss.
Therapy for Multiple Sclerosis is developed for neurodegenerative issues.
Therapy for schizophrenia is explored for psychiatric treatment needs.
Funding Insights of Pasithea
Pasithea has successfully raised a total of $1.46M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.4 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.46M
- Total Rounds 3
- Last Round Post-IPO — $30.4M
- First Round $250,000
(Jan 2021)
All 3 funding rounds of Pasithea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $30.4M | Post-IPO | – | – | – |
| Mar 2021 | $1.21M | Series A | – | – | – |
| Jan 2021 | $250,000 | Seed | – | – | – |
People of Pasithea
2 people are tracked at Pasithea (2 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Tiago Reis Marques | CEO | Leadership |
Lawrence Steinman | Co-Founder | Leadership |
Complete people profiles for Pasithea
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Pasithea
Pasithea is a publicly listed company on the NASDAQ with ticker symbol KTTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Sep 2021
- Listed onNASDAQ: KTTA
- Listed entityPasithea Therapeutics Corp.
- Exchange sectorHealth technology
- ISINUS70261F2020
- Share price$0.47 (+6.03% on the day) · 2026-10-09
- Market capitalisation$15.6M
- EPS (diluted, trailing year)$-1.58
- Volume (last session)60,594
Financials of Pasithea
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$20.4M | -$16.0M |
| 2024 | – | -$13.9M | -$13.6M |
| 2023 | – | -$16.0M | -$15.3M |
| 2022 | – | -$13.9M | -$12.6M |
| 2021 | $15,060 | -$2.2M | -$4.5M |
Detailed financial statements for Pasithea
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pasithea
Pasithea has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Allomek Therapeutics and Alpha-5 Integrin.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Targeted small molecule therapeutics for cancer are developed. | allomek.com | Farmington, United States | 2010 | Oct 2022 | •••• | |
Monoclonal antibodies are developed for treating neurological disorders. | alpha5integrin.tcc.mode | – | 0 | Jun 2022 | $3.75M |
Complete acquisition details for Pasithea
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Pasithea
6 dated milestones of Pasithea across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Pasithea is founded.
- Funding First funding round of $250K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.4M.
- Acquisition Acquires Alpha-5 Integrin.
- Acquisition Acquires Allomek Therapeutics.
Competitors of Pasithea
Pasithea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. | |
| cerecor.com | 2011 | Baltimore, United States | $45.2M | 20 | Therapeutics for immunological and neurological disorders are developed. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| vandapharma.com | 2003 | – | $33.5M | 203 | Pharmaceutical products for CNS disorders are developed and commercialized. | |
| hmnc-brainhealth.com | 2010 | Munich, Germany | $24.64M | – | Targeted therapies and personalized tests for neuropsychiatric disorders are developed. | |
| evecxia.com | 2013 | Durham, United States | $14.85M | – | Therapies for CNS disorders are developed by Evecxia Therapeutics. |
Detailed competitors of Pasithea
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pasithea
The website of Pasithea (pasithea.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▼ 11.4% vs previous month
Latest news on Pasithea
Complete news archive for Pasithea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Pasithea
10 companies that operate in the same segment as Pasithea (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pasithea
Pasithea was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Pasithea is headquartered in Miami Beach, United States. It is registered at Miami Beach, Florida, United States.
Tiago Reis Marques is the current CEO of Pasithea.
Pasithea is a funded company, having raised a total of $1.46M across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Jan 2021.
Pasithea has 4 employees.
Pasithea, a biotechnology company, is engaged in the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company is dedicated to creating therapeutics for conditions such as Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and schizophrenia. Research efforts are concentrated on addressing unmet medical needs in these areas, targeting both benign and cancerous tumors, neurodegenerative diseases, and psychiatric illnesses. Solutions are being developed to improve patient outcomes across these critical health sectors.
Pasithea's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Pasithea offers Neurofibromatosis Type 1 Therapy, Amyotrophic Lateral Sclerosis Therapy, Multiple Sclerosis Therapy, and Schizophrenia Therapy.
Yes, Pasithea is publicly traded on NASDAQ under the ticker symbol KTTA.
Pasithea has made 2 acquisitions, including Allomek Therapeutics, and Alpha-5 Integrin.
Pasithea operates through Pasithea Therapeutics.